Aytu biopharma announces exclusive agreement with medomie pharma ltd. to commercialize adzenys xr-odt(r) and cotempla xr-odt(r) in israel and the palestinian authority

After the completion of local regulatory approvals, aytu anticipates exporting to medomie both of its novel, orally disintegrating, extended-release tablets for the treatment of adhd englewood, co and givatayim, israel / accesswire / july 31, 2023 / aytu biopharma, inc. (the company or "aytu") (nasdaq:aytu), a pharmaceutical company focused on commercializing novel therapeutics, and medomie pharma ltd, a privately owned pharmaceutical company focused on distributing and selling innovative branded medicines, biosimilars and niche generic products for patients in israel and the palestinian authority, today announced the signing of an exclusive collaboration, distribution and supply agreement for aytu's adzenys xr-odt® and cotempla xr-odt® product lines. medomie will seek local regulatory approvals and marketing authorizations for both adzenys and cotempla.
AYTU Ratings Summary
AYTU Quant Ranking